Focus:
InterveXion Therapeutics’ 126-patient Phase I/II trial of IXT-m200 to combat methamphetamine addiction is expected to close enrolment next month, with just a few more patients left to recruit.
MedDay Pharmaceuticals announced that its multiple sclerosis (MS) drug MD1003 had failed to meet its primary and secondary endpoints in a Phase III trial (SPI2) for the treatment of non-active...
On 4 March, UCB announced the initiation of a Phase III clinical trial evaluating the efficacy and safety of dapirolizumab pegol (DZP) as an add-on treatment to standard of care...
March is multiple sclerosis (MS) awareness month. According to the National Multiple Sclerosis Society, nearly one million people are living with the disease in the US.
In light of the coronavirus (Covid-19) outbreak, GlobalData has analysed the five largest Covid-19 clinical trials in terms of participant size. GDCT0379047 (ChiCTR2000029573) and GDCT0379500 (ChiCTR2000029602) are the two largest...
The coronavirus outbreak, though the majority of cases have been in China, has affected many aspects of global life, especially businesses and travel. The virus can be easily spread from...
Earlier this month, vTv Therapeutics announced positive phase two results for its oral antidiabetic drug, TTP-399, when used as an adjunct therapy to insulin in type one diabetes (T1D) patients....
The Commonwealth Scientific and Industrial Research Organization’s (CSIRO) Melbourne-based factory has begun production of a test dose for a potential vaccine for novel coronavirus (Covid-19). Researchers from the University of...
According to the Consensus Drug Forecasts on GlobalData Pharma Intelligence Center, out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020,...
GlobalData analysed the number of clinical trials examining conjunctivitis with start dates between January 1, 2009 and February 13, 2020.
